Inclusion-body myositis and Alzheimer disease: Two sides of the same coin, or different currencies altogether?

Neurology

Volumn 66, Issue 2 SUPPL. 1, 2006, Pages

  Murphy, M Paul ^a,c   Golde, Todd E ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CLIOQUINOL; GAMMA SECRETASE INHIBITOR; GREEN TEA EXTRACT; IBUPROFEN; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; BACE1 PROTEIN, MOUSE; MUSCLE PROTEIN; NERVE PROTEIN; PROTEINASE; SECRETASE;

AGING; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ANTIINFLAMMATORY ACTIVITY; CLINICAL FEATURE; CONFERENCE PAPER; DEMENTIA; DRUG EFFICACY; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; INCLUSION BODY MYOSITIS; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE WEAKNESS; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; RISK REDUCTION; TRANSGENIC MOUSE; ANIMAL; CELL INCLUSION; CHEMISTRY; COMPARATIVE STUDY; DISEASE MODEL; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE; PASSIVE IMMUNIZATION; PATHOLOGY; PROTEIN PROCESSING; REVIEW; ULTRASTRUCTURE;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ENDOPEPTIDASES; DISEASE MODELS, ANIMAL; ENDOPEPTIDASES; HUMANS; IMMUNIZATION; IMMUNIZATION, PASSIVE; INCLUSION BODIES; MICE; MICE, TRANSGENIC; MUSCLE PROTEINS; MYOSITIS, INCLUSION BODY; NERVE TISSUE PROTEINS; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 33644869496     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000192108.02654.ac     Document Type: Conference Paper

References (49)

1. Oldfors A, Lindberg C. Inclusion body myositis. Curr Opin Neurol 1999;12:527-533.
2. Askanas V, Engel WK. Sporadic inclusion-body myositis and its similarities to Alzheimer disease brain. Recent approaches to diagnosis and pathogenesis, and relation to aging. Scand J Rheumatol 1998;27:389-405.
3. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001;81:741-766.
4. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-356.
5. Askanas V, Alvarez RB, Engel WK. Beta-amyloid precursor epitopes in muscle fibers of inclusion body myositis. Ann Neurol 1993;34:551-560.
6. Askanas V, Engel WK. Inclusion-body myositis: newest concepts of pathogenesis and relation to aging and Alzheimer disease. J Neuropathol Exp Neurol 2001;60:1-14.
7. Askanas V, Engel WK. Newest pathogenetic considerations in inclusion-body myositis: possible role of amyloid-beta, cholesterol, relation to aging and to Alzheimer's disease. Curr Rheumatol Rep 2002;4:427-433.
8. Askanas V, Engel WK, Alvarez RB. Light and electron microscopic localization of beta-amyloid protein in muscle biopsies of patients with inclusion-body myositis. Am J Pathol 1992;141:31-36.
9. Sarkozi E, Askanas V, Johnson SA, Engel WK, Alvarez RB. Beta-amyloid precursor protein mRNA is increased in inclusion-body myositis muscle. Neuroreport 1993;4:815-818.
10. Askanas V, McFerrin J, Baque S, Alvarez RB, Sarkozi E, Engel WK. Transfer of beta-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. Proc Natl Acad Sci U S A 1996;93:1314-1319.
11. Fukuchi K, Pham D, Hart M, Li L, Lindsey JR. Amyloid-beta deposition in skeletal muscle of transgenic mice: possible model of inclusion body myopathy. Am J Pathol 1998;153:1687-1693.
12. Jin LW, Hearn MG, Ogburn CE, et al. Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis. Am J Pathol 1998;153:1679-1686.
13. Sugarman MC, Yamasaki TR, Oddo S, et al. Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proc Natl Acad Sci U S A 2002;99:6334-6339.
14. Rochette MJ, Murphy MP. Gamma-Secretase: substrates and inhibitors. Mol Neurobiol 2002;26:81-95.
15. Cao X, Sudhof TC. A transcriptively active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 2001;293:115-120.
16. Gao Y, Pimplikar SW. The gamma-secretase-cleaved C-terminal fragment of amyloid precursor protein mediates signaling to the nucleus. Proc Natl Acad Sci U S A 2001;98:14979-14984.
17. Kimberly WT, Zheng JB, Guenette SY, Selkoe DJ. The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner. J Biol Chem 2001;276:40288-40292.
18. Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001;293:1491-1495.
19. Lewis J, Dickson DW, Lin WL, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001;293:1487-1491.
20. Kayed R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003;300:486-489.
21. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002;416:535-539.
22. Cai X-D, Golde TE, Younkin SG. Release of excess amyloid β protein from a mutant amyloid A protein precursor. Science 1993;259:514-517.
23. Citron M, Oltersdorf T, Haass C, et al. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 1992;360:672-674.
24. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996;2:864-870.
25. 717) mutants. Science 1994;264:1336-1340.
26. Nilsberth C, Westlind-Danielsson A, Eckman CB, et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced protofibril formation. Nat Neurosci 2001;4:887-893.
27. Price DL, Sisodia SS, Borchelt DR. Genetic neurodegenerative diseases: the human illness and transgenic models. Science 1998;282:1079-1083.
28. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996;47:425-432.
29. Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 2003;112:440-449.
30. Lim GP, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 2000;20:5709-5714.
31. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Ab42 independently of cyclooxygenase activity. Nature 2001;414:212-216.
32. Sagi SA, Weggen S, Eriksen J, Golde TE, Koo EH. The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of kappa B kinase, and NF kappa B, do not reduce amyloid beta 42 production. J Biol Chem 2003;278:31825-31830.
33. Weggen S, Eriksen JL, Sagi SA, et al. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J Biol Chem 2003;278:31831-31837.
34. Beher D, Clarke EE, Wrigley JD, et al. Selected Non-steroidal Anti-inflammatory Drugs and Their Derivatives Target (gamma)-Secretase at a Novel Site: evidence for al allosteric mechanism. J Biol Chem 2004;279:43419-43426.
35. Lleo A, Berezovska O, Herl L, et al. Nonsteroidal anti-inflammatory drugs lower Abeta(42) and change presenilin 1 conformation. Nat Med 2004;10:1065-1066.
36. Kukar T, Murphy MP, Eriksen JL, et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med 2005;11:545-550.
37. Murphy MP, Uljon SN, Fraser PE, et al. Presenilin 1 regulates pharmacologically distinct gamma -secretase activities. Implications for the role of presenilin in gamma -secretase cleavage. J Biol Chem 2000;275:26277-26284.
38. Bard F, Cannon C, Barbour R, et al. Peripherally adminstered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nat Med 2000;6:916-919.
39. Janus C, Pearson J, McLaurin J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000;408:979-982.
40. Bacskai BJ, Kajdasz ST, Christie RH, et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 2001;7:369-372.
41. Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE. Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging 2001;22:721-727.
42. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2001;98:8850-8855.
43. Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000;408:982-985.
44. Gouras GK, Tsai J, Naslund J, et al. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 2000;156:15-20.
45. LaFerla FM, Troncoso JC, Strickland DK, Kawas CH, Jay G. Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular Abeta stabilization. J Clin Invest 1997;100:310-320.
46. Yang AJ, Knauer M, Burdick DA, Glabe C. Intracellular A beta 1-42 aggregates stimulate the accumulation of stable, insoluble amyloidogenic fragments of the amyloid precursor protein in transfected cells. J Biol Chem 1995;270:14786-14792.
47. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004;43:321-332.
48. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001;30:665-676.
49. Levites Y, Amit T, Mandel S, Youdim MB. Neuroprotection and neurorescue against Abeta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate. Faseb J 2003;17:952-954.